Vishay Intertechnology

Phase A — Understand the business

Lens 1 · Company Overview

Vishay is one of the world's largest manufacturers of discrete semiconductors and passive electronic components — the cheap, ubiquitous, unglamorous parts that sit on virtually every circuit board ever made. It brands itself "The DNA of tech.". Six reportable segments span two families:

• Semiconductors: MOSFETs (Siliconix brand), Diodes, Optoelectronic Components.
• Passives: Resistors (the founding business — Bulk Metal foil, Dale, Power Metal Strip), Inductors (IHLP), Capacitors (Sprague, Vitramon, Roederstein, BCcomponents tantalum/ceramic/film/aluminum).

Founded 1962 by Dr. Felix Zandman around precision foil resistors; grown for 40 years primarily through acquisition ("Since 1985, we have pursued a business strategy of…growth through acquisitions" ). ~22,600 full-time employees as of 2025-12-31.

Customers / channel: virtually all major electronics OEMs and EMS firms, sold direct and through catalogue/independent distributors. Top 30 customers ≈ 74% of revenue; no single customer >10% — low single-name concentration, but the caveat is real: "certain subsidiaries and product lines… have customers which comprise greater than 10% of the subsidiary's or product line's net revenues". End markets: industrial (largest), automotive, mil/aero, healthcare, plus power/telecom/consumer/computing.

Contract structure: mostly book-and-ship + distribution, NOT take-or-pay. Backlog "includes only open orders we expect to ship in the next twelve months" and customers "may cancel or reschedule… in many instances without the payment of any penalty". This is the single most important structural fact about the demand signal everyone is now celebrating (see Lens 5 & 13): the $1.6B backlog is cancellable.

Lens 2 · Supply Chain

Upstream → Vishay → end customer:

• Inputs: silicon wafers (8" and now 12"), tantalum powder, base/precious metals (copper, palladium, nickel, tin — flagged repeatedly as a 2026 cost headwind), ceramics, packaging substrates. Some commodity products are outsourced to subcontractors/foundries to flex external capacity.
• Internal manufacturing (vertically integrated, ~global): the 10-K property schedule names fabs and plants across the US (Columbus NE, Bennington VT, Yankton SD, Warwick RI, Carson City/Niagara Falls/Marshall), Germany (Selb, Heide, Itzehoe — 8" fab + the new 12" fab), France (Nice, Chateau Gontier, Hyeres), Czech Republic (Blatna, Dolni Rychnov, Prachatice), Israel (Dimona, Migdal Ha'Emek, Be'er Sheva), China (Tianjin, Shanghai, Xi'an — diodes), India (Loni), Taiwan, Italy (Turin), Austria, Hungary.
• Capacity build (the cash story): Newport (Wales) wafer fab acquired from Nexperia in 2024; new 12" wafer fab in Itzehoe, Germany; new Mexico site for power inductors + non-linear resistors; resistor expansion in Mexico; expanded 8" diode capacity in Taiwan and Turin, Italy.
• Downstream: distributors (catalogue + strategic), OEMs, EMS.

Chokepoints / single-source: the Itzehoe 12" fab is the concentrated bet (~half of FY26 capex; "approximately half… invested in our 12-inch wafer fab" ). Substantially all cash sits offshore ("substantially all of our cash and cash equivalents and short-term investments were held by subsidiaries outside of the United States" ) — a structural liquidity chokepoint for US obligations (dividend, buyback, convert). Industry-wide, the 2025-26 Nexperia export-control crisis (China restricting Nexperia chip flows) created a discrete-semi supply scramble that pushed buyers toward second sources like Vishay.

Lens 3 · Competitive Advantages (moats)

A narrow, cyclical moat, not a wide one. Honest assessment:

• Breadth + one-stop-shop: "one of the broadest product lines of discrete semiconductors and passive components among our competitors". A field-application-engineer (FAE) sales motion lets a customer design Vishay parts across an entire board. Real but modest stickiness.
• Design-in / qualification switching costs: in automotive and mil/aero, parts are designed-in and qualified; ~certified+custom products are the majority of every passive segment's revenue (e.g. Resistors: 52% certified / 31% custom; Inductors: "substantially all… certified or custom"; Capacitors 44%/34%). These resist ASP erosion far better than commodity MOSFETs/diodes.
• Second-source value: management explicitly frames itself as benefiting from "industry consolidation… as an independent second-source supplier" — and the Nexperia disruption is that thesis paying off in real time.
• Brands/IP: Siliconix, Dale, Sprague, Vitramon, IHLP, Power Metal Strip, TrenchFET — recognized but not pricing-power brands the way TI/ADI analog franchises are.

Bargaining power: weak-to-moderate. Commodity products (35% of MOSFETs, 54% of Diodes ) face structural ASP erosion ("erosion of average selling prices of established products is typical for semiconductor products" ). Against giant rivals (Infineon, TI-adjacent, Murata, TDK, Yageo, STMicro — several "larger than us" ) Vishay is a price-taker in commodity lines and a price-holder only in specialty passives. Net: the moat is "broad catalogue + qualified specialty passives + second-source insurance," which protects volume share more than it protects margin.

Lens 4 · Segments

Six segments, FY2025 net revenues and the five-quarter trend through Q1-2026 — all `` (Financial Metrics by Segment table):

The story the segments tell:

• Inductors are the crown jewel — GM rose 20.9% → 31.8% and operating margin 16.5% → 27.4% over five quarters; "the inductors product line has grown significantly in recent years" on IHLP low-profile high-current parts feeding VRM/DC-DC converters (the AI-server power story).
• MOSFETs are the swing factor and the drag — GM cratered to 6.3% in Q2-25 (segment operating margin -9.7%), clawed back to 12.9% GM / +0.8% op margin in Q1-26. Highest book-to-bill (1.57) of any segment = where the cyclical snap-back is loudest, but margins are still thin. The Newport fab + MaxPower (Si/SiC) acquisition are bets on lifting this segment.
• Geography (Q1-26): Asia $335.1M / Europe $296.8M / Americas $207.3M. Roughly balanced — no single-region dependence.
• End market (Q1-26): Industrial $298.9M, Automotive $284.3M, Mil/Aero $89.2M, Healthcare $40.6M, Other $126.3M. Industrial + automotive ≈ 70% — both are the markets currently recovering from destock.

---

Phase B — Measure performance

Lens 5 · Earnings Result (latest print: Q1 FY2026, ended 2026-04-04)

The cleanest "cyclical trough is behind us" print Vishay has put up in two years.

• Revenue $839.2M, +17.3% YoY (vs $715.2M) and +4.8% QoQ (vs $800.9M Q4-25). Five-quarter sequential climb: 715.2 → 762.3 → 790.6 → 800.9 → 839.2.
• Gross margin 21.0%, up from 19.0% a year ago and 19.6% prior quarter — "higher sales volume and associated manufacturing efficiencies, which offset higher metals and materials costs". First 21-handle in the trend window.
• Operating income $22.1M (2.6% margin) vs $0.8M a year ago. Net earnings $7.2M, $0.05/diluted share vs a $(4.1)M loss a year ago. Profitability has just turned positive — but it is thin (2.6% operating margin on $839M).
• Demand signal: book-to-bill 1.34 (semis 1.47 / passives 1.23), backlog +21% to $1.59B from $1.12B a year ago — the highest in the five-quarter window. ASPs still falling (-1.1% QoQ "including tariff adders") — volume, not price, is doing the work.
• Guidance (Q2-26): revenue $875–905M, gross margin ~22.0% — a sequential acceleration and another margin step.
• Balance-sheet flags: cash $479.4M (down from $515.0M); inventory rose to $790.8M (from $759.2M) — building ahead of the ramp; receivables $369.2M (down). Operating cash flow $63.7M but capex $110.7M → FREE CASH FLOW −$46.9M. The print is GAAP-profitable and FCF-negative simultaneously — the defining tension.
• Market reaction: the stock is up ~400% over three months / ~290% over six. The market is pricing far more than a 2.6%-margin recovery quarter (see Lens 8/12/13).

Lens 6 · Earnings Calls (sentiment trend)

No transcripts on the research-layer shelf (transcripts/ empty) — this lens is ``-grounded on the Q1-26 call (2026-05-13) and management's written commentary.

• Tone: confidently inflecting, with a careful hedge. CEO Joel Smejkal: "Vishay's first quarter financial results demonstrate that the Vishay 3.0 strategy is working… Our top priority going forward is to increase backlog turns to ensure we maintain competitive lead times as consumption accelerates".
• The recurring phrases (vs. the 2024-25 destock calls): "capacity readiness," "reliably scaling with our customers," "high-growth, high-margin products," "modulate spending in response to order flow".
• The tell — a softened long-term commitment: on the 2028 targets, Smejkal said "The targets are still there, most of the targets". "Most" is doing work. Management is leaning bullish on the cycle while quietly trimming its multi-year guarantee — exactly when the stock is pricing the targets as a near-certainty.
• Shift over time: from "managing through the downturn / protecting fixed costs" (2024-25) to "scaling into the upturn / capturing early demand" (2026). Genuine inflection in language, matched by the order book.

Lens 7 · Comps

Peer set = global passives/discrete majors.

Read: the only sourced multiple is VSH's own ~28.6x trailing EV/EBITDA — "well above historical norms". For a low-margin (mid-single-digit operating margin), capital-intensive, cyclical components maker, a high-20s trailing EV/EBITDA is a peak-of-cycle / momentum multiple, not a durable one. The sell-side anchor is the FY28 framework: a Hold at $51 was struck on 9.19x eFY28 EV/EBITDA — i.e. even bulls justify today's price only by reaching three years forward to peak earnings. On current fundamentals the stock is expensive against any historical passives comp.

Lens 8 · Stock-Price Catalysts (what moves VSH)

The 2026 move is the most important price action in the company's history. Drivers, ``:

• The Q1-26 beat + raised outlook (May 2026): profitability turned positive, backlog +21%, B:B 1.34, Q2 guide up — the fundamental ignition.
• The Nexperia export-control crisis (late 2025 → 2026): China's restrictions on Nexperia (a key automotive discrete supplier) triggered a global second-source scramble; Vishay is a direct beneficiary as buyers diversify.
• The AI-server passives narrative: social/sell-side attention on MLCCs and high-current inductors (IHLP) into AI server power, with claims of >100% YoY TAM expansion in AI-server MLCCs. Vishay's Inductors segment (31.8% GM) is the cleanest read-through.
• Product launches (mid-June 2026): high-voltage IHDV inductors, Gen-7 Hyperfast rectifiers, ILHB automotive ferrite beads — reinforcing the "domestic/high-reliability power" angle.
• A short squeeze: short interest ~13.15% of float (11.52M shares, rising) — a heavily-shorted small-cap cyclical squeezing as the cycle turns explains the magnitude (~400%/3mo) beyond fundamentals.
• The $750M equity offering (priced 2026-06-30, $50/share): stock fell ~4.6% on the deal — issuance is now itself a catalyst, and a bearish one near-term.

Pattern: VSH historically reacts to the cycle (book-to-bill, ASP, destock/restock) more than to any single customer. The 2026 episode is cycle-turn + a genuine supply-disruption windfall + a short squeeze, amplified into a move far larger than the earnings justify.

---

Phase C — Judge people & books

Lens 9 · Management

• CEO Joel Smejkal (President & CEO since 2023-01-01): a 35-year Vishay lifer (joined 1990; ran Passive Components and Global Distribution Sales). Architect of "Vishay 3.0" — the capacity-led growth plan. Track record on this plan is still unproven: the strategy has so far produced three years of negative FCF and a GAAP loss in FY2025; the payoff (margin expansion, $5B revenue) is the forward bet.
• CFO David McConnell (since 2024-03): another lifer (joined 1992, ex-Corporate Treasurer).
• Executive Chairman Marc Zandman (son of founder Felix Zandman): the controlling presence. The Zandman family — Marc Zandman, Ruta Zandman, Ziv Shoshani — controls ~35% of total voting power via Class B super-voting stock as of 2025-12-31.
• Skin in the game / structure: dual-class. 12.1M Class B convertible shares carry outsized votes. This is a founder-controlled company run by long-tenured professional managers — deep institutional knowledge, but minority public holders cannot force change.
• Capital allocation: the defining question. (1) Growth-through-acquisition legacy (MaxPower Si/SiC; Nexperia's Newport fab, 2024). (2) A 3-year capex super-cycle: $329M (2023), $320M (2024), $273M (2025), guided $400–440M (2026). (3) A Stockholder Return Policy (adopted 2022) to return ≥70% of FCF — but FCF has been negative, so Vishay paid $54.2M dividends + $12.5M buybacks in 2025 out of the balance sheet/debt, not free cash. (4) A $750M equity raise at $50 (June 2026) to fund the build and pay down the credit line. ROE/ROIC are depressed by design during the build (FY2025 GAAP net loss on $2.09B equity ). Verdict: aggressive, conviction-led, counter-cyclical capital deployment — admirable if the demand is durable, value-destructive if 2026 proves to be a restock head-fake. They are betting the company's balance sheet (and now diluting holders) on the upturn being structural.
• Red flags: none egregious. Dual-class control + family chairman is the standing governance discount. Diluting at $50 right after a 400% run is shareholder-rational (sell high) but also a candid signal of where insiders see value.

Lens 10 · Forensic Red Flags

Accounting quality is clean-to-conservative; the risks are operational, not forensic.

• Cash vs. earnings: the gap is openly disclosed and benign — FCF is negative because of capex, not because earnings are non-cash. FY2025 operating cash flow $184.3M was healthy; FCF was −$87.8M purely from $273.3M capex. No earnings-quality red flag here — if anything GAAP understates cash generation ex-growth-capex.
• Inventory: rising ($759.2M → $790.8M QoQ ) into a backlog ramp — watch it; if the restock proves a head-fake, this is where the write-down lands (note: gross margin is explicitly reduced by "losses on purchase commitments and inventory write-downs" ).
• Goodwill/intangibles: Goodwill $180.4M, other intangibles $78.5M. A $66.5M goodwill impairment was taken in FY2024 — so management has already written down once; the remaining balance is modest vs. $4.2B assets. Impairment risk is contained.
• SBC / non-GAAP: Vishay's "adjusted" bridge is restrained — FY2025 GAAP net loss $(8.98)M vs adjusted net loss $(6.6)M — a small, honest adjustment (no heroic non-GAAP profit conjured from a GAAP loss). Good mark.
• Offshore cash: "substantially all" cash is held offshore; US obligations (dividend, buyback, convert) depend on repatriation (which triggers tax — $47.0M transition-tax installment in 2025) or the credit facility. A liquidity-geography risk, not an accounting one.
• Convertible 2030 notes ($750M, 0% coupon framing, due Sept 2030) + credit facility ($250M drawn) = $1.0B gross debt; conversion/fundamental-change repurchase mechanics could force cash payment.

Regulatory findings (required sub-section).

• SEC Litigation Releases / AAERs: none. Verified via regulatory/regulatory-findings.md (SEC EDGAR EFTS, LR + AAER, 2021-06-30 → 2026-06-30): total_sec_findings: 0.
• 10-K Item 3 (Legal Proceedings): management states routine litigation only, not material individually or in aggregate. Specific items: (1) environmental remediation at current/former sites incl. Superfund PRP obligations (a standing reserve, acquisition-inherited); (2) Vishay GSI v. USDOE/USA — a CERCLA cost-recovery case (E.D.N.Y.) over a predecessor's 1960-1993 Hicksville NY groundwater impact, which Vishay is contesting; (3) routine IP/patent licensing disputes typical of the discrete-semi sector. None flagged material.
• Non-SEC / historical: Vishay (via Vishay Polytech) was a participant in the global capacitors price-fixing antitrust litigation of the mid-2010s (settled; DOJ + multiple foreign regulators investigated the industry). Historical and pre-window — not in the SEC LR/AAER 2021-26 search, no current action — but a real datapoint on industry conduct and a reminder that commodity-passive pricing has an antitrust history.
• Conclusion: No material current regulatory or accounting findings — verified via SEC EDGAR EFTS (LR, AAER → 0), 10-K Item 3 (routine + environmental only), and web search (only a settled, historical capacitor-antitrust matter) as of 2026-06-30.

---

Phase D — Project & stress-test

Lens 11 · Forward Projection (no forecast.ts logged — watchlist mode)

Base unit: FY2025 actual revenue $3.069B, GAAP EPS $(0.07), adjusted EPS $(0.05). Q1-26 run-rate: $839M rev, $0.05 EPS. Share count rises ~10% post-offering (15M new shares on ~148M base incl. 12.1M Class B). Three fiscal years forward (FY2026 / FY2027 / FY2028), every line labeled, outputs ``:

FY2026 (cycle recovery year):

• Revenue: Q1 $839M + Q2 guide $890M, assume modest H2 continuation → **$3.55–3.65B**. ≈ +16% YoY.
• Gross margin ramps ~21% → ~22-23%; operating margin ~3% → ~5-6% on volume leverage.
• Base EPS ~$0.60–0.90. Bull ~$1.10 (margin overshoots on backlog turns); bear ~$0.30 (restock fades, ASP erosion + metals costs bite, inventory write-down).

FY2027:

• If the cycle holds and AI-server/auto demand is structural: revenue ~$3.9–4.2B, op margin ~8-10% → EPS ~$1.40–1.90. Bear (cycle rolls over): revenue flat-to-down, EPS back toward ~$0.50.

FY2028 (management's target year):

• Management framework: ~$5B revenue, low-30s% gross margin, "$5+" EPS. To hit $5+ EPS on ~150M shares = ~$750M net income on $5B revenue ≈ 15% net margin — roughly 5-6x the company's best-ever recent net margin and far above the mid-single-digit operating margins it earns today.
• My base FY2028 estimate: EPS ~$2.00–2.75. Bull (everything breaks right, specialty mix + Itzehoe yields lift structural margin): ~$3.50. Bear (it was a restock + squeeze; normalized FCF-negative cyclical): ~$1.00.

The fulcrum: at ~$52 the stock is ~19-26x my base FY2028 estimate three years out, or ~10x the company's own $5+ aspiration. The bull case requires you to believe the $5+ target — a margin transformation with no historical precedent for this asset mix. Not logged to forecast.ts (breadth mode); if promoted to a thesis, log "VSH FY28 non-GAAP EPS ≥ $3.00, p≈0.30."

Lens 12 · Bull vs Bear

Bull case. Vishay is a genuine cyclical inflection caught at the perfect moment: book-to-bill 1.34, backlog +21% to $1.6B, gross margin through 21% and guided to 22%, profitability just turned positive. The 3-year, ~$900M+ capex super-cycle (Newport, Itzehoe 12", Mexico, Taiwan/Italy) was spent into the downturn and now positions Vishay to "capture the early stages of upturns" with capacity rivals lack. Two secular tailwinds layer on the cycle: AI-server power (high-current IHLP inductors + MLCCs, the 31.8%-GM Inductors segment) and automotive/industrial electrification. The Nexperia crisis hands Vishay a second-source windfall. If "Vishay 3.0" delivers even half the path to $5B / low-30s GM, normalized earnings power dwarfs today's trough. Contrarian bull: the market has spent a decade pricing Vishay as a no-growth commodity melt; capacity + mix-shift to specialty passives is a real, underappreciated structural re-rate.

Bear case (2-3 permanent-impairment / de-rating risks).

1. It's a low-margin commodity cyclical wearing a growth multiple. ~28.6x trailing EV/EBITDA on 2.6% operating margins is a peak-multiple-on-peak-cycle setup. ASPs are still falling (-1.1% QoQ ); the recovery is pure volume. When the restock normalizes, both the multiple and the earnings compress together — the classic semis-cyclical double-whammy.
2. The backlog is cancellable. Vishay itself warns orders can be cancelled/rescheduled "without the payment of any penalty". A 1.34 book-to-bill in a supply-scramble (Nexperia) is exactly the environment that breeds double-ordering. If 2026 is a restock + fear-buying head-fake, the $1.6B backlog evaporates and inventory (already rising) gets written down.
3. The capital model doesn't self-fund. Three straight years of negative FCF; a "return 70% of FCF" policy funded from the balance sheet; and now a $750M dilutive raise at $50. Management selling ~10% of the company right after a 400% run is the single loudest signal that insiders think fair value is near $50, not $69 — and it caps the float-squeeze that drove the move.

Pre-mortem (18 months out, thesis broke): It's late 2027. The Nexperia disruption resolved, double-orders cancelled, book-to-bill fell below 1.0 by mid-2026, ASP erosion + metals costs squeezed the margin ramp, the $750M of new shares diluted EPS, the Itzehoe fab came on into a softening market (fixed-cost under-absorption), and the stock round-tripped from ~$52 to the high teens/$20s — converging on where the sell-side fair values ($17.50-$34) always sat.

Are multiples too high? Yes, on any current or historical-cyclical basis. They are only defensible by underwriting the FY2028 $5+ EPS target at high probability — which has no precedent in this asset mix.

Contrarian view (what the market refuses to see): The bears' fair-value cluster ($17.50-$34) may under-weight the structural mix-shift — Inductors at 31.8% GM and specialty passives are a different, stickier business than the legacy commodity melt, and AI-server power demand could make this capex cycle the one that finally re-rates the normalized margin. The market refusing to see it cuts both ways: bulls refuse to see a cancellable backlog + dilution; bears may refuse to see a genuine mix transformation.

Lens 13 · Devil's Advocate (short-seller)

Dismantling the bull case.

• What structurally breaks the money-machine: ASP erosion is permanent and structural in commodity discretes (MOSFETs 35% commodity, Diodes 54% ); volume recoveries are temporary, price erosion is forever. A capacity build into a price-eroding commodity is how you manufacture negative operating leverage at the next trough — more fixed cost to under-absorb.
• Revenue concentration / what shifts: no single customer >10%, but ~70% is industrial+automotive — both are the most destock/restock-whippy end markets, and automotive demand is precisely what the Nexperia panic distorted. If the panic-buying reverses, the two biggest end markets roll together.
• Why the moat is weaker than bulls think: Vishay is "one of" the broadest — but it competes against larger players (Infineon, Murata, TDK, STMicro, Yageo ) in every line. "Second-source" is a position of structurally lower pricing power, not a moat — you win volume by being the backup, and you lose it the moment the primary's supply normalizes (which is already happening as China grants Nexperia exemptions ).
• Most dangerous competitor bulls underestimate: Yageo + the Asian passives bloc (Murata, TDK, Taiyo Yuden) in MLCCs/inductors — they have scale, cost, and are equally levered to the same AI-server passives TAM. The AI-MLCC story is not Vishay-proprietary; it accrues to whoever has the lowest cost and most capacity, which is not Vishay.
• Worst capital-allocation moves: funding a "70% of FCF return" policy while FCF is negative (paying dividends out of debt/balance sheet ); and the $750M raise at $50 right after the run — dilution at a price insiders evidently find attractive to sell.
• What must hold for today's price: (1) the FY2028 $5+ EPS target — unprecedented margin; (2) the backlog is real demand, not double-orders; (3) the ~13% short squeeze doesn't unwind; (4) AI-server passives TAM accrues meaningfully to Vishay specifically. Break any one and ~$52 is indefensible.
• Growth disappoints 20-30%: if FY2026 revenue lands ~$3.0-3.2B (vs ~$3.6B implied) and margins stall, EPS is ~$0.30-0.50 and a normalized cyclical multiple (~10-12x EBITDA) puts the stock in the high-teens-to-$20s — i.e. the sell-side fair value, a 55-65% drawdown from current.
• Single permanent-impairment scenario (and plausibility): the AI-server passives narrative proves to accrue to Asian MLCC leaders, and the Nexperia windfall reverses, and Itzehoe comes on into a soft market → structural under-absorption + a goodwill/inventory write-down + the dilution. Plausibility: moderate. Not a fraud, not a zero — a great-business-this-is-not cyclical that round-trips a momentum/squeeze move.

Lens 14 · Management Questions (ordered by information value)

1. The 2028 framework is "$5B revenue, low-30s gross margin, $5+ EPS." On the Q1 call you said "most of the targets" still hold — which target did you drop, and why now?
2. You just raised $750M at $50 right after a 400% run. Why equity over debt, and what does pricing the deal at $50 say about your own view of intrinsic value?
3. Book-to-bill is 1.34 and backlog +21% — how much of that order strength is genuine end-consumption vs. customers double-ordering/safety-stocking around the Nexperia disruption? What's your cancellation-rate assumption?
4. ASPs are still falling (-1.1% QoQ) while volumes recover. At what point in this cycle do ASPs inflect positive, and which segments never will?
5. To reach low-30s gross margin from ~22% is a structural transformation. Bridge it for me — how much is volume/absorption, how much is mix-shift to specialty passives, how much is cost-out?
6. You're spending $400-440M capex in 2026, ~half on Itzehoe. What backlog/utilization level would make you halt or slow Itzehoe, and how late can you pull that lever?
7. The Stockholder Return Policy returns ≥70% of FCF, but FCF has been negative three years. Is the dividend funded from operations or the balance sheet, and at what point is it at risk?
8. Substantially all cash is offshore. What's your US liquidity runway for the dividend, buyback, and the 2030 convert without further repatriation tax or borrowing?
9. Inductors run 31.8% gross margin and are your AI-server play. What share of the AI-server power-passives TAM do you realistically capture vs. Murata/TDK/Taiyo Yuden, and why you?
10. The Newport fab (from Nexperia) and MaxPower (Si/SiC) target MOSFETs — your lowest-margin segment (0.8% op margin). What's the path to double-digit MOSFET operating margin, and by when?
11. The 2030 convertible notes ($750M): what's the conversion/refinance plan, and how does the recent share-price move change the dilution math?
12. Tariffs and metals/materials costs are a recurring headwind. What's the net tariff/cost drag on FY2026 gross margin, and how much can you pass through given falling ASPs?
13. Inventory rose QoQ into the ramp. What's your inventory-turn target, and what triggers a write-down if demand softens?
14. The dual-class structure gives the Zandman family ~35% of votes. How do you weigh minority-holder interests in major capital decisions like this raise?
15. You've grown by acquisition for 40 years. With the balance sheet now funding a capex super-cycle, is M&A on hold, and what would you buy if it weren't?

---